Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
Eur Heart J
; 28(18): 2208-16, 2007 Sep.
Article
em En
| MEDLINE
| ID: mdl-17681958
ABSTRACT
AIMS:
Anaemia is common in chronic heart failure (CHF) and associated with worse outcome. This randomized, double-blind, placebo-controlled study evaluated the effect of two darbepoetin alfa dosing regimens on haemoglobin (Hb) rate of rise and clinical effects in patients with CHF and anaemia. METHODS ANDRESULTS:
Patients with CHF (>or=3 months), left ventricular ejection fraction (LVEF)CONCLUSION:
In this study of patients with CHF and anaemia, treatment with darbepoetin alfa raised Hb using different dosing regimens. Darbepoetin alfa improved some quality of life indices, but its safety requires further exploration. Larger trials are needed to determine the effects on long-term morbidity and mortality.
Buscar no Google
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
/
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Eritropoetina
/
Insuficiência Cardíaca
/
Hematínicos
/
Anemia
Tipo de estudo:
Clinical_trials
Aspecto:
Patient_preference
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Eur Heart J
Ano de publicação:
2007
Tipo de documento:
Article